Compare

Indaptus Therapeutics/$INDP

1D1W1M3M6MYTD1Y5YMAX

About Indaptus Therapeutics

Indaptus Therapeutics Inc is a clinical biotechnology company that has developed a novel and patented systemically-administered anti-cancer and anti-viral immunotherapy. Its approach is based on the hypothesis that efficient activation of both innate and adaptive immune cells and associated anti-tumor and anti-viral immune responses will require a multi-targeted package of immune system activating signals that can be administered safely intravenously. Its patented technology is composed of single strains of attenuated and killed, non-pathogenic, Gram-negative bacteria, designed to have reduced i.v. toxicity, but largely uncompromised ability to prime or activate many of the cellular components of innate and adaptive immunity. Its candidate, Decoy20 is for patients with solid tumors.
Ticker
$INDP
Sector
Health
Primary listing
NASDAQ
Employees
5
Headquarters
New York, United States
Website
indaptusrx.com

INDP Metrics

BasicAdvanced
$493M
-
-$0.47
1.18
-

Bulls say / Bears say

A June private placement lifted cash and short-term investments to $11.6 million at 30 June, with management saying this should fund planned operations through the second quarter of 2027. A separate $24 million placement was later agreed, although its closing was still conditional in the latest filing reviewed. (GlobeNewswire, SEC)
The patented Decoy platform has shown broad anti-tumour activity in preclinical models, while the company reported immune-biomarker activation and early stable-disease signals in its past Decoy20 study. Those preliminary signals could support future licensing or partnering, though they do not establish clinical benefit. (SEC)
A research collaboration with Kunming University of Science and Technology opens a new line of work in neurological disorders and sleep. Indaptus is also considering strategic transactions or investments, which could give the company another route to build value if it finds a suitable opportunity. (SEC, GlobeNewswire)
Indaptus has stopped enrolling its Decoy20 combination study, has no participants in ongoing Decoy20 studies and has no active clinical development programmes. With no new trial planned, the company currently lacks a clinical catalyst for its former lead asset. (SEC)
The company issued 20 million shares for $12 million in June and later agreed to a further placement of about 20.3 million shares for $24 million. The later deal's closing deadline was extended, leaving both substantial dilution and execution uncertainty in view. (SEC, SEC)
Indaptus used $8.9 million of cash in operations in the first half of 2026 and reported an accumulated deficit of $85.6 million. It has no approved products or product-sales revenue, and its filing says there is substantial doubt about its ability to continue as a going concern. (SEC)
Data summarised monthly by Lightyear AI. Last updated on 4 Nov 2026.

INDP Financial Performance

Revenues and expenses
Income statement
QuarterlyAnnual
Q3 24
QoQ growth
Revenue
Net income
Profit margin

INDP Earnings Performance

Company profitability
Earnings per share
QuarterlyAnnual
Q4 23
Q1 24
Q2 24
Q3 24
Q4 24
Actual
Expected
Surprise
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.